Ralliant Corporation (NYSE:RAL – Get Free Report) has been given a consensus rating of “Hold” by the twelve brokerages that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $50.50.
A number of analysts have issued reports on the company. Citigroup decreased their price target on Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a research note on Friday, February 6th. Oppenheimer dropped their price objective on shares of Ralliant from $60.00 to $50.00 and set an “outperform” rating for the company in a research note on Friday, February 6th. Zacks Research lowered shares of Ralliant from a “hold” rating to a “strong sell” rating in a report on Monday, February 9th. Royal Bank Of Canada decreased their target price on shares of Ralliant from $52.00 to $41.00 and set a “sector perform” rating on the stock in a research report on Friday, February 6th. Finally, Barclays lowered their target price on shares of Ralliant from $60.00 to $52.00 and set an “overweight” rating for the company in a report on Monday, February 9th.
Check Out Our Latest Analysis on Ralliant
Insider Buying and Selling at Ralliant
Institutional Trading of Ralliant
A number of institutional investors have recently modified their holdings of RAL. Vanguard Group Inc. lifted its position in Ralliant by 10.7% during the third quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company’s stock valued at $637,995,000 after buying an additional 1,415,327 shares in the last quarter. Dodge & Cox increased its position in shares of Ralliant by 13.3% in the fourth quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock worth $621,849,000 after acquiring an additional 1,434,376 shares in the last quarter. Viking Global Investors LP acquired a new stake in shares of Ralliant in the second quarter worth $257,200,000. Millennium Management LLC raised its stake in shares of Ralliant by 172.4% in the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock valued at $253,175,000 after acquiring an additional 3,147,660 shares during the period. Finally, State Street Corp purchased a new position in shares of Ralliant in the 2nd quarter valued at $213,096,000.
Ralliant Trading Down 2.6%
Shares of RAL opened at $40.03 on Friday. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $57.02. The company has a market capitalization of $4.47 billion and a PE ratio of 20.42. The stock has a fifty day moving average of $46.16 and a two-hundred day moving average of $46.70. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.58 and a current ratio of 0.84.
Ralliant (NYSE:RAL – Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.02. The business had revenue of $554.60 million for the quarter, compared to analyst estimates of $543.04 million. The business’s revenue for the quarter was up 1.2% compared to the same quarter last year. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.
Ralliant Dividend Announcement
The business also recently disclosed a quarterly dividend, which was paid on Monday, March 23rd. Stockholders of record on Monday, March 9th were paid a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, March 9th. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. Ralliant’s payout ratio is currently 10.20%.
Ralliant Company Profile
Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
Featured Articles
Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.
